Market Overview:
The global cell and gene therapy manufacturing QC market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for precision therapies, rising prevalence of chronic diseases, and growing investments in R&D activities for cell and gene therapies. The global cell and gene therapy manufacturing QC market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into safety testing, purity testing, potency testing, identity testing stability testing. On the basis of application;the market is segmented into precision therapy biological research Other applications). Geographically;the global cell and gene therapy manufacturing QCmarketis segmented into North America Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Cell and gene therapy manufacturing QC is the process of ensuring the quality of cell and gene therapies during their manufacture. This is important because it helps ensure that the therapies are safe and effective.
Safety Testing:
Safety testing is a procedure carried out to evaluate the quality of products manufactured in cell and gene therapy manufacturing QC market. It ensures that products meet all the required specifications before being distributed as finished goods for use by healthcare professionals and patients. The factors such as regulatory changes, technological advancements, product design & development, raw material sourcing & quality assurance are expected to drive safety testing demand over the forecast period.
Purity Testing:
Purity testing is a process to test the quality of products and ensure that they meet all legal requirements before it is distributed or sold to the customer. It ensures that products are free from any contaminants, such as bacteria, which can cause disease when consumed by humans or animals.
The cell and gene therapy manufacturing QC market has been growing rapidly due to rising demand for advanced therapies across the globe.
Application Insights:
Precision therapy manufacturing dominated the global market in 2017. This can be attributed to growing usage of cell and gene therapies for treating various incurable diseases. Precision medicine is based on the concept that treatment should be targeted to the specific genetic makeup of a patient, which will help in healing him/her faster with fewer side effects. Thus, rising demand for precision manufactured cells and genes is anticipated to drive growth over the forecast period.
The biological research segment accounted for a significant share owing to increasing government funding towards this field of study from countries like U.S., Canada, China and India. Growing focus on infectious disease management through introduction of new vaccines is also expected to boost product demand over next eight years (from 2018to 2030).
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of biopharmaceutical manufacturing facilities and increasing R&D activities. The region is expected to maintain its dominance during the forecast period due to continuous developments in healthcare infrastructure, rising adoption of new technologies, and high prevalence of chronic diseases that can be treated using cell & gene therapy products.
Asia Pacific regional market is anticipated to grow at a lucrative rate over the forecast period owing to an increase in government funding for stem cell research and development as well as growing demand for regenerative medicine. Japan has approved Regenerative Medicine Law since April 2014 which supports clinical trials involving cells, tissue, and genes derived from human embryos under specific conditions. In addition, China launched a national strategy on March 11th 2018 focusing on developing innovative therapies through advanced cellular therapies based on iPS technology (Induced Pluripotent Stem Cells).
Growth Factors:
- Increasing demand for cell and gene therapies due to their potential to cure various diseases
- Growing number of clinical trials for cell and gene therapies
- Rising number of approvals for cell and gene therapies by regulatory authorities
- Technological advancements in the field of cell and gene therapy manufacturing QC that improve the efficiency and accuracy of tests performed
- Increasing awareness about the benefits of cell and gene therapies among healthcare professionals
Scope Of The Report
Report Attributes
Report Details
Report Title
Cell and Gene Therapy Manufacturing QC Market Research Report
By Type
Safety Testing, Purity Testing, Potency Testing, Identity Testing, Stability Testing
By Application
Precision Therapy, Biological Research
By Companies
Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A., Sistemic Scotland Limited, Thermo Fisher Scientific Inc., Vigene Biosciences, Inc., WuXi AppTec
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Cell and Gene Therapy Manufacturing QC Market Report Segments:
The global Cell and Gene Therapy Manufacturing QC market is segmented on the basis of:
Types
Safety Testing, Purity Testing, Potency Testing, Identity Testing, Stability Testing
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Precision Therapy, Biological Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bio-Techne Corporation
- BioMerieux SA
- Catalent, Inc.
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd
- Intertek Group plc
- Lonza Group AG
- Merck KGaA
- Sartorius AG
- SGS S.A.
- Sistemic Scotland Limited
- Thermo Fisher Scientific Inc.
- Vigene Biosciences, Inc.
- WuXi AppTec
Highlights of The Cell and Gene Therapy Manufacturing QC Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Safety Testing
- Purity Testing
- Potency Testing
- Identity Testing
- Stability Testing
- By Application:
- Precision Therapy
- Biological Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cell and Gene Therapy Manufacturing QC Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cell and gene therapy manufacturing QC is the process of ensuring that products manufactured using cells or genes are safe and effective. This includes verifying that the cells or genes used in a product are properly sourced, testing for any potential contaminants, and ensuring that the product meets all required regulatory standards.
Some of the major players in the cell and gene therapy manufacturing qc market are Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A., Sistemic Scotland Limited, Thermo Fisher Scientific Inc., Vigene Biosciences, Inc., WuXi AppTec.
The cell and gene therapy manufacturing qc market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cell and Gene Therapy Manufacturing QC Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cell and Gene Therapy Manufacturing QC Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cell and Gene Therapy Manufacturing QC Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cell and Gene Therapy Manufacturing QC Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cell and Gene Therapy Manufacturing QC Market Size & Forecast, 2018-2028
4.5.1 Cell and Gene Therapy Manufacturing QC Market Size and Y-o-Y Growth
4.5.2 Cell and Gene Therapy Manufacturing QC Market Absolute $ Opportunity
Chapter 5 Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
5.2.1 Safety Testing
5.2.2 Purity Testing
5.2.3 Potency Testing
5.2.4 Identity Testing
5.2.5 Stability Testing
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
6.2.1 Precision Therapy
6.2.2 Biological Research
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cell and Gene Therapy Manufacturing QC Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cell and Gene Therapy Manufacturing QC Analysis and Forecast
9.1 Introduction
9.2 North America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
9.6.1 Safety Testing
9.6.2 Purity Testing
9.6.3 Potency Testing
9.6.4 Identity Testing
9.6.5 Stability Testing
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
9.10.1 Precision Therapy
9.10.2 Biological Research
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cell and Gene Therapy Manufacturing QC Analysis and Forecast
10.1 Introduction
10.2 Europe Cell and Gene Therapy Manufacturing QC Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
10.6.1 Safety Testing
10.6.2 Purity Testing
10.6.3 Potency Testing
10.6.4 Identity Testing
10.6.5 Stability Testing
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
10.10.1 Precision Therapy
10.10.2 Biological Research
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cell and Gene Therapy Manufacturing QC Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cell and Gene Therapy Manufacturing QC Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
11.6.1 Safety Testing
11.6.2 Purity Testing
11.6.3 Potency Testing
11.6.4 Identity Testing
11.6.5 Stability Testing
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
11.10.1 Precision Therapy
11.10.2 Biological Research
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cell and Gene Therapy Manufacturing QC Analysis and Forecast
12.1 Introduction
12.2 Latin America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
12.6.1 Safety Testing
12.6.2 Purity Testing
12.6.3 Potency Testing
12.6.4 Identity Testing
12.6.5 Stability Testing
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
12.10.1 Precision Therapy
12.10.2 Biological Research
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cell and Gene Therapy Manufacturing QC Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cell and Gene Therapy Manufacturing QC Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cell and Gene Therapy Manufacturing QC Market Size Forecast by Type
13.6.1 Safety Testing
13.6.2 Purity Testing
13.6.3 Potency Testing
13.6.4 Identity Testing
13.6.5 Stability Testing
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cell and Gene Therapy Manufacturing QC Market Size Forecast by Applications
13.10.1 Precision Therapy
13.10.2 Biological Research
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cell and Gene Therapy Manufacturing QC Market: Competitive Dashboard
14.2 Global Cell and Gene Therapy Manufacturing QC Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bio-Techne Corporation
14.3.2 BioMerieux SA
14.3.3 Catalent, Inc.
14.3.4 Charles River Laboratories International Inc.
14.3.5 Eurofins Scientific SE
14.3.6 F. Hoffmann-La Roche Ltd
14.3.7 Intertek Group plc
14.3.8 Lonza Group AG
14.3.9 Merck KGaA
14.3.10 Sartorius AG
14.3.11 SGS S.A.
14.3.12 Sistemic Scotland Limited
14.3.13 Thermo Fisher Scientific Inc.
14.3.14 Vigene Biosciences, Inc.
14.3.15 WuXi AppTec
